GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PaxMedica Inc (OTCPK:PXMD) » Definitions » 5-Day RSI

PaxMedica (PaxMedica) 5-Day RSI : 41.77 (As of May. 16, 2024)


View and export this data going back to 2022. Start your Free Trial

What is PaxMedica 5-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 5-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.

As of today (2024-05-16), PaxMedica's 5-Day RSI is 41.77.

The industry rank for PaxMedica's 5-Day RSI or its related term are showing as below:

PXMD's 5-Day RSI is ranked better than
64.42% of 1571 companies
in the Biotechnology industry
Industry Median: 49.14 vs PXMD: 41.77

Competitive Comparison of PaxMedica's 5-Day RSI

For the Biotechnology subindustry, PaxMedica's 5-Day RSI, along with its competitors' market caps and 5-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PaxMedica's 5-Day RSI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PaxMedica's 5-Day RSI distribution charts can be found below:

* The bar in red indicates where PaxMedica's 5-Day RSI falls into.



PaxMedica  (OTCPK:PXMD) 5-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PaxMedica  (OTCPK:PXMD) 5-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 5-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.


PaxMedica 5-Day RSI Related Terms

Thank you for viewing the detailed overview of PaxMedica's 5-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


PaxMedica (PaxMedica) Business Description

Traded in Other Exchanges
N/A
Address
303 South Broadway, Suite 125, Tarrytown, NJ, USA, 10591
PaxMedica Inc is a clinical-stage biopharmaceutical company focusing on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms, ranging from neurodevelopmental disorders, including autism spectrum disorder (ASD), to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a debilitating physical and cognitive disorder believed to be viral in origin and now with rising incidence globally due to the long term effects of SARS-CoV-2 (COVID-19). The company's product candidate under development is PAX-101, an intravenous formulation of suramin, which it is developing for multiple indications, including East African HAT, ASD, ME/CFS, and LCS.
Executives
Zachary Rome director, officer: Chief Operating Officer C/O TIMBER PHARMACEUTICALS, INC., 900 E. HAMILTON AVENUE, SUITE 100, CAMPBELL CA 95008
Michael Derby director, officer: Executive Chairman 303 SOUTH BROADWAY, SUITE 125, TARRYTOWN NY 10591
Howard J. Weisman director, officer: Chief Executive Officer C/O PAXMEDICA, INC., 900 E. HAMILTON AVENUE, SUITE 100, CAMPBELL CA 95008
Karen Larochelle director 900 E. HAMILTON AVENUE, SUITE 100, CAMPBELL CA 95008
John F Coelho director 22 BENEDICT CRESCENT, BASKING RIDGE NJ 07920
Charles J Casamento director 99 BELBROOK WAY, ATHERTON CA 94027
David W. Hough officer: Chief Medical Officer C/O PAXMEDICA, INC., 900 E. HAMILTON AVENUE, SUITE 100, CAMPBELL CA 95008
Tardimed Sciences Llc 10 percent owner 303 SOUTH BROADWAY, SUITE 125, TARRYTOWN NY 10591
Stephen Sheldon officer: Chief Financial Officer 2 REVOLUTIONARY WAY, #312, HOPKINTON MA 01748